degenerative lumbar/sacral spine disease degenerative lumbar/sacral disc disease lumbar/sacral scoliosis herniated lumbar/sacral disc nefopam degenerative lumbar spine spine surgery enhanced recovery after surgery postoperative pain
Conditions
Interventions
Patient in this group will received 20 mg of nefopam in 100 mL of normal saline intravenous drip during the operation and 80 mg of nefopam in 500 mL of normal saline intravenous drip in 24 hours post&
operation.,Patient in this group will received normal saline intravenous drip during the operation and 500 mL of normal saline intravenous drip in 24 hours post-
operation.
Placebo Comparator Drug,Active Comparator Drug
Nefopam group,Placebo
Sponsors
none
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: patients who undergo lumbar/sacral spine surgery ASA physical status 1-3
Exclusion criteria
Exclusion criteria: History of drug allergy (which is used in this study) History of epilepsy, coronary heart disease, glaucoma current use of MAO inhibitors drug liver cirrhosis or end stage renal failure tumor of infection around the surgical site history of spine surgery in previous 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Opioid consumption in first 24 hours after surgery 24 hours after surgery mg | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain recovery room, post-operative day 1-3 VAS,ambulation after surgery time to first sit, time to first walk, length of stay,complication after surgery from analgesic drugs and surgery | — |
Countries
Thailand
Contacts
Public ContactNattapat Tangchitcharoen
Orthopaedic department, Faculty of Medicine, Chulalongkorn University
Outcome results
None listed